Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And this is in addition to a very, very strong demand for the – from the Cryogene asset as well |
| On the bioservices side, things are very, very consistent and strong |
| What I mean by that is, when you take a close look, you will see that our quarterly results contain some very promising growth points, including a notable increase in commercial and cell and gene therapy revenue |
| In fact, commercial revenue increased 54% on a year-over-year basis and 52% sequentially |
| As Jerry mentioned, we’re already seeing very strong interest |
| You’re seeing additional uptake in revenue acceleration out of our portfolio of existing products and, obviously, our support of the Sarepta product has also been a nice contributor to that number for the quarter |
| Nice growth in the quarter, up 50% year – over 50% year-over-year |
| By continuing to execute on this strategy, we believe Cryoport will emerge as an even stronger company that is well positioned to achieve long-term profitable growth |
| So, we have been very successful in pulling share on the new client basis, as well as retaining in our existing trial base with our existing clients |
| But at the same time, we see a significant opportunity for us, really, to further bolster our leadership position and to capture more wallet share from these customers that are poised to grow quite significantly over the next years |
| During the quarter, MVE and some 70% of – with some 70% of the world market continues to produce healthy financial metrics |
| So we remain quite confident about our long-term market outlook and the recovery of our China market as the country, despite its current economic lows, is a hot bed for the life sciences |
| So that’s very, very positive |
| As you see that revenue grow and as you see us leveraging the assets and the capabilities, specifically in the cell and gene therapy space, you will see that EBITDA margin grow with that as well |
| Cryoport is poised to capitalize on the continued growth of the life sciences and especially the cell and gene industry, as more therapies make their way towards commercialization over these coming years |
| Really strong growth |
| Having said that, we are continuing to see solid and sustained demand from our key life sciences and cell and gene therapy customers despite the current macroeconomic climate |
| With these latest developments and our leading market positions, we have even greater belief that our long-term growth prospects are solid |
| Great to see the strong revenue from commercial cell and gene therapies |
| MVE is in a solid position |
| Cryoport Systems supports approximately 70% of all the cell and gene therapy clinical trial market, and as we continue building out our global supply chain solutions, that share continues to grow even in a challenging environment |
| So the story is even broader than just the Vertex – CRISPR Vertex product because we’re seeing an acceleration in the commercial filing and activity space, which we think is going to continue to drive that, that strong performance we had in our commercial revenue for the quarter |
| These are all customer-driven, market-driven projects with great potential |
| So when the facilities come online in we believe that will be a very, very nice and quick uptake with that asset as it comes online |
| We’ve actually onboarded 29 new clients into those facilities over the last 18 months, which is a very, very strong base |
| On the commercial side, as Tom had mentioned, filing activity is very strong |
| And maybe let me just add real quick to MVE, because I think sometimes people overlook that in spite of the revenue level right now in Q2 and Q3, if you look at our product revenue for Q3, the product revenue gross margin is at 45% and the MVE business has been very profitable driving good positive adjusted EBITDA and cash flow |
| All this growth was driven by the sustainable demand we saw during the quarter and that we are continuing to see from advanced therapy manufacturers |
| They have been very strong in Asia-Pac and Europe |
| We are actually seeing a very nice monetization of the services that have launched |
| Statement |
|---|
| Some of them had revenue below Street expectations |
| So we heard some of the cell and gene therapy manufacturers weakness in 4Q |
| So, I think the manufacturing capacity issues, we have largely caught up to it, I think |
| Jerrell Shelton I’m sorry, you’re coming through on the phone very weak |
| Although it is to be candid lower than what we are forecasting at midyear |
| But what we can tell you is that there has been some reserve as a result of the foreign corrupt practices |
| The vertex sickle cell anemia therapy, I think you’ve mentioned that in the past, what level of involvement will you have there, is my first question? And then the second question is, if you look back on the MVE, which had its period of softness, but it seems to be stabilizing |
| And then, of course, we have to pull back in China, which we think will stabilize |
| It is going to be a mixed bag in Q4 based on what they’re telling the Street |
| I am just wondering if you are seeing any logistical challenges with all the – obviously, the war in Europe and then now the Israel-Gaza situation |
| So, just wondering if you are seeing any disruptions in logistics on that front? Jerrell Shelton Nothing of significance, right now, we have had disruptions in the past |
| We fell a little bit short on the U.S |
| And so people are lying low |
| Was it kind of overstock globally and then what portion was just tighter CapEx budgets? Thanks |
| In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections |
| But with the volatility in the space, we are seeing still a fair deal of trials that are either being completed or terminated or suspended on a quarter-by-quarter basis |
| And what I was referring to is the order intake is stabled out, it’s flattened out and we think that it will continue to be stabilized |
| So, first one on – I am wondering if you are getting any feedback from some of the commercial providers, I mean you said commercial therapies capacity, we are hearing sporadically and with different drugs that the supply is constrained on the cell therapy side |
| Unidentified Analyst You talked about MVE demand starting to stabilize in China |
Please consider a small donation if you think this website provides you with relevant information